Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia

Published:2014-07 Issue:7 Volume:4 Page:e225-e225
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer Journal

Author:

Bassan R,Spinelli O,Oldani E,Intermesoli T,Tosi M,Peruta B,Borlenghi E,Pogliani E M,Di Bona E,Cassibba V,Scattolin A M,Romani C,Ciceri F,Cortelezzi A,Gianfaldoni G,Mattei D,Audisio E,Rambaldi A

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/bcj201448.pdf

Reference15 articles.

1. Bruggemann M, Raff T, Kneba M . Has MRD monitoring superseded other prognostic factors in adult ALL? Blood 2012; 120: 4470–4481.

2. Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009; 113: 4153–4162.

3. Gokbuget N, Kneba M, Raff T, Trautmann H, Bartram CR, Arnold R et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 2012; 120: 1868–1876.

4. Ribera JM, Oriol A, Morgades M, Montesinos P, Sarrà J, González-Campos J et al. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of PETHEMA ALL-HR-03. J Clin Oncol 2014; 32: 1595–1604.

5. Spinelli O, Peruta B, Tosi M, Guerini V, Salvi A, Zanotti MC et al. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica 2007; 92: 612–618.

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Need for consensus on primary end points and efficacy definitions in trials for adult acute lymphoblastic leukemia;Blood Advances;2024-08-13

2. Laboratory validation and clinical utility of next-generation sequencing-based IGH/TCR clonality testing for the monitoring of measurable residual disease in acute lymphoblastic leukaemia: real-world experience at Austin Pathology;Pathology;2024-07

3. Management of ALL in adults: 2024 ELN recommendations from a European expert panel;Blood;2024-05-09

4. Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study;Blood;2023-11-23

5. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades;Journal of Hematology & Oncology;2023-03-16